Holen Sie sich die Stockscreener-App
9.99
0.50%
0.05
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Can Ocular Therapeutix Inc. stock surprise with earnings upsideJuly 2025 Intraday Action & Technical Buy Zone Confirmation - Naître et grandir
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Ocular Therapeutix (OCUL) Is Up 16.2% After Detailing Retinal Pipeline Progress And Upcoming Milestones - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Bought by Vanguard Group Inc. - MarketBeat
Ocular Therapeutix Opens with 8.61% Gain Amid Ongoing Financial Challenges - Markets Mojo
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation - simplywall.st
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Stea - GuruFocus
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Grows By 27.8% - MarketBeat
William Blair Maintains Outperform on Ocular Therapeutix, Inc. (OCUL) March 2026 - Meyka
Ocular Therapeutix Breaks Above 200-Day Moving AverageBullish for OCUL - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 17.4%Should You Buy? - MarketBeat
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix at TD Cowen Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Canada
OCUL: Superiority achieved in retina study, paving way for broad label and premium market position - TradingView
Ocular Therapeutix Director Pravin Dugel Sells Shares - TradingView
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations - Yahoo Finance
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Yahoo Finance
Ocular Therapeutix Shares Fall After Inflation Report | 2026 Market UpdateNews and Statistics - IndexBox
Ocular Therapeutix (NASDAQ:OCUL) Cut to Sell at Wall Street Zen - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflecting Its Recent Volatility And DCF Implied Upside - simplywall.st
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why - Yahoo Finance
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress - TipRanks
Ocular Therapeutix to Release SOL-1 Phase 3 AXPAXLI Trial Slides at Macula Society Meeting - TradingView
Ocular Therapeutix chief development officer Kaiser sells $23k in stock - Investing.com India
Sanjay Nayak Sells 1,759 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Peter Kaiser Sells 2,810 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $166,063.68 in Stock - MarketBeat
Ocular Therapeutix, Inc. (OCUL) Investor Outlook: A Biotech With A 205% Potential Upside - DirectorsTalk Interviews
Ocular Therapeutix (NASDAQ:OCUL) Insider Nadia Waheed Sells 3,510 Shares - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Director Richard Md Lindstrom Acquires 60,229 Shares - MarketBeat
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock By Investing.com - Investing.com Canada
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock - Investing.com South Africa
Ocular Therapeutix Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Ocular Therapeutix to Participate in March Investor Conferences - Bitget
Ocular Therapeutix™ to Participate in March Investor Conferences - The Manila Times
Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD - MarketBeat
Ocular To Present Detailed Phase 3 SOL-1 Data For AXPAXLI At The 49th Macula Society Annual Meeting - Nasdaq
A Look At Ocular Therapeutix (OCUL) Valuation After Axpaxli Phase 3 SOL-1 Data And Share Price Drop - simplywall.st
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations - The Manila Times
Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals - Yahoo Finance
Needham cuts Ocular Therapeutix stock price target on trial results By Investing.com - Investing.com Canada
Tech Rally: Will Ocular Therapeutix Inc. face regulatory challengesJuly 2025 Movers & Weekly Momentum Stock Picks - mfd.ru
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ocular Therapeutix (OCUL) and Sanofi (SNY) - The Globe and Mail
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.5%What's Next? - MarketBeat
Ocular Therapeutix Sees Mixed Results with Wet AMD Trial Boost and Stocks Dive - StocksToTrade
Ocular Therapeutix’s Axpaxli Hits Key Milestone in Eye Treatment - timothysykes.com
Needham Maintains Buy Rating on OCUL but Lowers Price Target | O - GuruFocus
Needham cuts Ocular Therapeutix stock price target on trial results - Investing.com
Needham & Company LLC Has Lowered Expectations for Ocular Therapeutix (NASDAQ:OCUL) Stock Price - MarketBeat
1.30%
20.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):